About
AMS Israel develops protein-free tissue adhesives based on proprietary alga-mimetic formulations for use in a wide range of surgical applications. The company's adhesive technology mimics the underwater adherence mechanism of algae. AMS's first product, Seal-V, is a surgical sealant designed for use in various vascular procedures. Seal-V has proven to be safe, effective, cost effective, strong, biocompatible, biodegradable, and easy to use. Seal-V can adhere to both native and synthetic vessels, positioning it as a solution to control bleeding in vascular surgeries. The company's other products include Seal-G, a gastrointestinal bioresorbable sealant designed to secure gastrointestinal anastomoses to decrease lethal complications resulting from postsurgical leaks, and the Orthopedic Adhesion Barrier, an extra-articular bioresorbable gel designed to speed the recovery of injured joints by preventing tissue adhesions, thereby reducing disabling complications following surgical or nonsurgical joint injuries. AMS Israel's technology has been developed under the umbrella of the Alfred Mann Institute at the Technion. In 2018, the company received the CE mark for its Seal-G surgical sealant for gastrointestinal procedures.
Funding history · 1 round · — total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Sealantis' primary focus in medical technology?
- Sealantis develops protein-free tissue adhesives based on proprietary alga-mimetic formulations for a wide range of surgical applications, mimicking the underwater adherence mechanism of algae.
- When was Sealantis acquired and by whom?
- Sealantis was acquired by Advanced Medical Solutions Group in January 2019 for $25 million.
- What is Seal-V and its intended use?
- Seal-V is Sealantis' first product, a surgical sealant designed for use in various vascular procedures to control bleeding by adhering to both native and synthetic vessels.
- When did Sealantis receive CE marking for its Seal-G product?
- Sealantis received the CE mark for its Seal-G surgical sealant for gastrointestinal procedures in January 2018.
- What is the purpose of Seal-G?
- Seal-G is a gastrointestinal bioresorbable sealant designed to secure gastrointestinal anastomoses, aiming to decrease lethal complications from postsurgical leaks.
- What is the Orthopedic Adhesion Barrier product by Sealantis?
- The Orthopedic Adhesion Barrier is an extra-articular bioresorbable gel designed to prevent tissue adhesions and speed recovery of injured joints, reducing complications after surgical or non-surgical joint injuries.
- Who was a lead investor in Sealantis' undisclosed funding round in November 2016?
- Teuza was a lead investor in Sealantis' undisclosed funding round in November 2016.
- Where was Sealantis' technology developed?
- Sealantis' technology was developed under the umbrella of the Alfred Mann Institute at the Technion.